News and Events

News

All categories

Earnings

Press Release

All years

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 26, 2022

Affimed to Present at the 2022 Jefferies Healthcare Conference

May 26, 2022

Affimed Announces Annual General Meeting of Shareholders

May 24, 2022

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

May 24, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

May 16, 2022

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

May 12, 2022

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

May 6, 2022

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

April 27, 2022

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 18, 2022

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

April 13, 2022

Events

All

Scientific

Investors

03Jun

ASCO Annual Meeting

June 3 - 7, 2022 (Chicago, US)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed to Present at the 2022 Jefferies Healthcare Conference

Affimed Announces Annual General Meeting of Shareholders

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

Events

ASCO Annual Meeting